{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:03:58Z","timestamp":1784887438933,"version":"3.55.0"},"reference-count":33,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,4,29]],"date-time":"2013-04-29T00:00:00Z","timestamp":1367193600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2013,4,29]],"date-time":"2013-04-29T00:00:00Z","timestamp":1367193600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatr Blood Cancer"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1002\/pbc.24547","type":"journal-article","created":{"date-parts":[[2013,4,29]],"date-time":"2013-04-29T12:38:51Z","timestamp":1367239131000},"page":"1447-1451","source":"Crossref","is-referenced-by-count":49,"title":["Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors"],"prefix":"10.1002","volume":"60","author":[{"given":"Lars","family":"Wagner","sequence":"first","affiliation":[{"name":"Division of Oncology, Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine; Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Turpin","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine; Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaram","family":"Nagarajan","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine; Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Weiss","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine; Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Cripe","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine; Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Geller","sequence":"additional","affiliation":[{"name":"Division of Oncology, Cincinnati Children's Hospital Medical Center; University of Cincinnati College of Medicine; Lexington, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,29]]},"reference":[{"key":"10.1002\/pbc.24547-BIB0001|pbc24547-cit-0001","first-page":"4110","article-title":"Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair protein phenotypes in xenograft models","volume":"6","author":"Houghton","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24547-BIB0002|pbc24547-cit-0002","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and temozolomide for Ewing sarcoma: The Memorial Sloan-Kettering experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0003|pbc24547-cit-0003","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pbc.20697","article-title":"Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma","volume":"48","author":"Wagner","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0004|pbc24547-cit-0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1200\/JCO.2010.31.7107","article-title":"Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: A Children's Oncology Group study","volume":"29","author":"Bagatell","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0005|pbc24547-cit-0005","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1200\/JCO.2006.07.1720","article-title":"Two consecutive Phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group","volume":"25","author":"Pappo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0006|pbc24547-cit-0006","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1002\/pbc.22407","article-title":"Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study","volume":"54","author":"Wagner","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0007|pbc24547-cit-0007","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/pbc.22460","article-title":"Extended Phase I evaluation of vincristine, irinotecan, temozolomide, and antibiotic in children with refractory solid tumors","volume":"54","author":"McNall-Knapp","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0008|pbc24547-cit-0008","article-title":"Vincristine, irinotecan, and temozolomide for treatment of relapsed alveolar rhabdomyosarcoma","author":"Mixon","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1002\/pbc.24547-BIB0009|pbc24547-cit-0009","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/pbc.22410","article-title":"Oral irinotecan for treatment of pediatric solid tumors: Ready for prime time","volume":"54","author":"Wagner","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0010|pbc24547-cit-0010","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1634\/theoncologist.2011-0148","article-title":"Clinical development of VEGF signaling pathway inhibitors in childhood solid tumors","volume":"16","author":"Glade Bender","year":"2011","journal-title":"Oncologist"},{"key":"10.1002\/pbc.24547-BIB0011|pbc24547-cit-0011","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/1078-0432.CCR-04-1201","article-title":"Vascular endothelial growth factor: A therapeutic target for tumors of the Ewing's sarcoma family","volume":"11","author":"Dalal","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24547-BIB0012|pbc24547-cit-0012","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1203\/01.pdr.0000242494.94000.52","article-title":"The anti-VEGF antibody bevacizumab potently reduces the growth rate of high-risk neuroblastoma xenografts","volume":"60","author":"Segerstr\u00f6m","year":"2006","journal-title":"Pediatr Res"},{"key":"10.1002\/pbc.24547-BIB0013|pbc24547-cit-0013","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1002\/pbc.24547-BIB0014|pbc24547-cit-0014","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1158\/1078-0432.CCR-06-2309","article-title":"Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma","volume":"13","author":"Vredenburgh","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24547-BIB0015|pbc24547-cit-0015","doi-asserted-by":"crossref","first-page":"3942","DOI":"10.1158\/1078-0432.CCR-07-0278","article-title":"Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy","volume":"13","author":"Dickson","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24547-BIB0016|pbc24547-cit-0016","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2119\/molmed.2011.00120","article-title":"In vivo topoisomerase I inhibition attenuates the expression of hypoxia-inducible factor 1\u03b1 target genes and decreases tumor angiogenesis","volume":"18","author":"Gu\u00e9rin","year":"2012","journal-title":"Mol Med"},{"key":"10.1002\/pbc.24547-BIB0017|pbc24547-cit-0017","doi-asserted-by":"crossref","first-page":"2544","DOI":"10.1200\/JCO.2005.02.477","article-title":"Phase I\/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1\/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer","volume":"23","author":"Herbst","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0018|pbc24547-cit-0018","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pbc.21935","article-title":"Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan","volume":"52","author":"Packer","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0019|pbc24547-cit-0019","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/pbc.22868","article-title":"Bevacizumab and irinotecan in the treatment of children with recurrent\/refractory medulloblastoma","volume":"56","author":"Aguilera","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0020|pbc24547-cit-0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/pbc.21280","article-title":"Reducing irinotecan-associated diarrhea in children","volume":"50","author":"Wagner","year":"2008","journal-title":"Pediatr Blood Cancer"},{"key":"10.1002\/pbc.24547-BIB0021|pbc24547-cit-0021","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1002\/pbc.24547-BIB0022|pbc24547-cit-0022","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MPH.0b013e31826b9d25","article-title":"Gemcitabine, docetaxel, and bevacizumab in relapsed and refractory pediatric sarcomas","volume":"34","author":"Hingorani","year":"2012","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1002\/pbc.24547-BIB0023|pbc24547-cit-0023","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1200\/JCO.2006.06.7272","article-title":"Irinotecan plus temozolomide for relapsed or refractory neuroblastoma","volume":"24","author":"Kushner","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0024|pbc24547-cit-0024","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1097\/MPH.0b013e3181b2598c","article-title":"Treatment of relapsed\/refractory pediatric sarcomas with gemcitabine and docetaxel","volume":"31","author":"Mora","year":"2009","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1002\/pbc.24547-BIB0025|pbc24547-cit-0025","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.9552","article-title":"Feasibility of bevacizumab ombined with vincristine, topotecan, and cyclophosphamide in patients with first recurrent Ewing sarcoma: A Children's Oncology Group study","volume":"28","author":"Leavey","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0026|pbc24547-cit-0026","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1200\/JCO.2007.11.9230","article-title":"Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children's Oncology Group study","volume":"26","author":"Glade Bender","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0027|pbc24547-cit-0027","doi-asserted-by":"crossref","first-page":"5081","DOI":"10.1158\/1078-0432.CCR-12-0078","article-title":"A Phase I Trial and Pharmacokinetic Study of Aflibercept (VEGF Trap) in Children with Refractory Solid Tumors: A Children's Oncology Group Phase I Consortium Report","volume":"18","author":"Glade Bender","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24547-BIB0028|pbc24547-cit-0028","doi-asserted-by":"crossref","first-page":"abstr 9501","DOI":"10.1200\/jco.2011.29.15_suppl.9501","article-title":"Phase I study of pazopanib in children with relapsed or refractory solid tumors (ADVL0815): A Children's Oncology Group Phase I Consortium trial","volume":"29","author":"Glade Bender","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0029|pbc24547-cit-0029","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1200\/JCO.2010.30.9674","article-title":"A phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumors","volume":"28","author":"Fox","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1002\/pbc.24547-BIB0030|pbc24547-cit-0030","doi-asserted-by":"crossref","first-page":"6011","DOI":"10.1158\/1078-0432.CCR-11-3284","article-title":"A Phase I Trial and Pharmacokinetic Study of Sorafenib in Children with Refractory Solid Tumors or Leukemias: A Children's Oncology Group Phase I Consortium Report","volume":"18","author":"Widemann","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24547-BIB0031|pbc24547-cit-0031","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-11-0237","article-title":"Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: A Children's Oncology Group study","volume":"17","author":"Dubois","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1002\/pbc.24547-BIB0032|pbc24547-cit-0032","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft tissue sarcoma (PALETTE: A randomized, double-blind, placebo-controled Phase 3 trial","volume":"379","author":"Van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1002\/pbc.24547-BIB0033|pbc24547-cit-0033","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/annonc\/mdr151","article-title":"A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: An Italian Sarcoma Group study","volume":"23","author":"Grignani","year":"2012","journal-title":"Ann Oncol"}],"container-title":["Pediatric Blood & Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24547","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.24547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/pbc.24547\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T15:54:49Z","timestamp":1715270089000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.24547"}},"subtitle":["VOIT With Bevacizumab for Recurrent Pediatric Tumors"],"short-title":[],"issued":{"date-parts":[[2013,4,29]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"URL":"https:\/\/doi.org\/10.1002\/pbc.24547","archive":["Portico"],"relation":{},"ISSN":["1545-5009"],"issn-type":[{"value":"1545-5009","type":"print"}],"subject":[],"published":{"date-parts":[[2013,4,29]]}}}